Abstract Details

Title Effects of Alemtuzumab on Disability and Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS)

Topic Multiple Sclerosis

Presentation(s) P5 - (-)

Poster/Presentation
Number 356

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Regina Berkovich, MD, PhD (Regina Berkovich MD PhD Inc) PRESENTER	The institution of Dr. Berkovich has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Alexion, Biogen, Genentec, Mallincrodt, Sanofi, Novartis, . Dr. Berkovich has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, Genentec, Sanofi, Merck . Dr. Berkovich has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Alexion, Biogen, Sanofi, Merck, Mallincrodt . The institution of Dr. Berkovich has received research support from Biogen, Sanofi, Merck.

��ɫ��